Search

Displaying results 5281 - 5290 of 7540 in total
  1. Drug

    Denufosol

    go.drugbank.com/drugs/DB04983
    Investigational

    Denufosol has not gained FDA approval, and clinical trials with this drug have ceased since 2011.

  2. Drug

    SGN-15

    go.drugbank.com/drugs/DB05818
    Investigational

    Monoclonal antibodies are substances that are made in the laboratory and that can locate and bind to cancer cells. Doxorubicin is a type of anthracycline antitumor antibiotic.

  3. Drug

    Gavestinel

    go.drugbank.com/drugs/DB06741
    Experimental

    Highly potent and selective non-competitive antagonist acting at the strychnine-insensitive glycine binding site of the NMDA receptor-channel complex (Kd = 0.8 nM).

  4. Drug

    Vanillyl butyl ether

    go.drugbank.com/drugs/DB11299
    Approved

    It is added to food products as a flavoring agent.

  5. Drug

    Prolectin-M

    go.drugbank.com/drugs/DB16521
    Investigational

    [L31343] It is being investigated in the clinical trial NCT04512027 (Prolectin-M in COVID-19 Patients Having Mild to Moderate Symptoms Not Requiring Oxygen Support. (Prolectin-M)).

  6. Drug

    Benziodarone

    go.drugbank.com/drugs/DB13277
    ApprovedWithdrawn

    It was withdrawn from France markets and British markets due to its effects causing Jaundice in patients [T487, A175636].

  7. Drug

    Taliglucerase alfa

    go.drugbank.com/drugs/DB08876
    Approved

    Taliglucerase alfa is the recombinant active form of the human lysosomal enzyme, β-glucocerebrosidase. It was approved in 2012 and is marketed under the name Elelyso for use in patients with type 1 Gaucher's disease.

  8. Drug

    Belnacasan

    go.drugbank.com/drugs/DB05507
    Investigational

    VX-765 is currently under clinical development for the treatment of inflammatory and autoimmune conditions, as it blocks the hypersensitive response to an inflammatory stimulus.

  9. Drug

    NGX267

    go.drugbank.com/drugs/DB05152
    Investigational

    It is developed for the treatment of Alzheimer’s disease and has shown the potential to both reduce symptoms and slow disease progression.

  10. Drug

    Zosuquidar

    go.drugbank.com/drugs/DB06191
    Investigational

    It is now in "Phase 3" of clinical tests in the United States. Its action mechanism consists of the inhibition of P-glycoproteins; other drugs with this mechanism include tariquidar and laniquidar.